Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01798303 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2940094 in Participants With Alcohol Dependency
A Phase 2 study of Alcoholism, sponsored by BlackThorn Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
- 5
- Study locations
NCT01798303: Completed Phase 2 study of Alcoholism, sponsored by BlackThorn Therapeutics.
NCT01798303 is a Phase 2 study of Alcoholism that has completed, run by BlackThorn Therapeutics. The registered enrollment target is 88 participants, below the 374-participant average among 65 other Alcoholism trials with a reported enrollment target (76% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01798303, a Phase 2 study of Alcoholism, has completed, sponsored by BlackThorn Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
- 5
- Study locations
Study Summary
The main purpose of this study is to evaluate a once daily (QD) 40-milligram (mg) oral dose of LY2940094 in participants with an alcohol dependency to evaluate if LY2940094 will reduce alcohol drinking in these participants. The study will last for 8 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY2940094
Study Locations (5)
Connecticut
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - New Haven
Florida
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - North Miami
Indiana
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Indianapolis
Oregon
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Portland
South Carolina
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
What the finished NCT01798303 record still lists
NCT01798303 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 374-participant average among 65 other Alcoholism trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Alcoholism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01798303 lists 5 locations in 5 states (Connecticut, Florida, Indiana).
Frequently Asked Questions
What is clinical trial NCT01798303 about?
NCT01798303 is a clinical study titled "A Study of LY2940094 in Participants With Alcohol Dependency". The main purpose of this study is to evaluate a once daily (QD) 40-milligram (mg) oral dose of LY2940094 in participants with an alcohol dependency to evaluate if LY2940094 will reduce alcohol drinking in these participants. The study will last for 8 weeks.
What is the current status of trial NCT01798303?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2013-07. Estimated completion is 2014-06.
What conditions does trial NCT01798303 study?
This clinical trial studies the following conditions: Alcoholism.
What interventions are being tested in trial NCT01798303?
The interventions under investigation include: Placebo (DRUG), LY2940094 (DRUG).
Who is sponsoring clinical trial NCT01798303?
This trial is sponsored by BlackThorn Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01798303 being conducted?
This trial has 5 study locations across Connecticut, Florida, Indiana, Oregon, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01798303's enrollment target sits among peer trials
88 38th of 65 higher than 27 of 65 other Alcoholism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcoholism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketamine Alcohol (in Treatment-Resistant Depression)
RECRUITING · Phase 2
-
Ibudilast for Treating Alcohol Use Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Gabapentin Treatment of Alcohol Dependence
COMPLETED · Phase 2
-
Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients
COMPLETED · Phase 2
-
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
COMPLETED · Phase 2
-
Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia